268 related articles for article (PubMed ID: 18001077)
21. Peptide targeting of tumor lymph vessels.
Laakkonen P; Zhang L; Ruoslahti E
Ann N Y Acad Sci; 2008; 1131():37-43. PubMed ID: 18519957
[TBL] [Abstract][Full Text] [Related]
22. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).
Meyer-Losic F; Quinonero J; Dubois V; Alluis B; Dechambre M; Michel M; Cailler F; Fernandez AM; Trouet A; Kearsey J
J Med Chem; 2006 Nov; 49(23):6908-16. PubMed ID: 17154520
[TBL] [Abstract][Full Text] [Related]
23. Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand.
Kim Y; Lillo AM; Steiniger SC; Liu Y; Ballatore C; Anichini A; Mortarini R; Kaufmann GF; Zhou B; Felding-Habermann B; Janda KD
Biochemistry; 2006 Aug; 45(31):9434-44. PubMed ID: 16878978
[TBL] [Abstract][Full Text] [Related]
24. Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides.
Bidwell GL; Davis AN; Raucher D
J Control Release; 2009 Apr; 135(1):2-10. PubMed ID: 19095020
[TBL] [Abstract][Full Text] [Related]
25. Cell-penetrating properties of the transactivator of transcription and polyarginine (R9) peptides, their conjugative effect on nanoparticles and the prospect of conjugation with arsenic trioxide.
Kanwar JR; Gibbons J; Verma AK; Kanwar RK
Anticancer Drugs; 2012 Jun; 23(5):471-82. PubMed ID: 22241171
[TBL] [Abstract][Full Text] [Related]
26. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide.
Lindgren M; Rosenthal-Aizman K; Saar K; Eiríksdóttir E; Jiang Y; Sassian M; Ostlund P; Hällbrink M; Langel U
Biochem Pharmacol; 2006 Feb; 71(4):416-25. PubMed ID: 16376307
[TBL] [Abstract][Full Text] [Related]
27. A novel chemical approach to drug delivery: lipidic amino acid conjugates.
Toth I
J Drug Target; 1994; 2(3):217-39. PubMed ID: 7812692
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and in vitro activity of novel drug delivery systems containing tuftsin derivatives and methotrexate.
Bai KB; Láng O; Orbán E; Szabó R; Köhidai L; Hudecz F; Mezö G
Bioconjug Chem; 2008 Nov; 19(11):2260-9. PubMed ID: 18959436
[TBL] [Abstract][Full Text] [Related]
29. TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
Yang W; Luo D; Wang S; Wang R; Chen R; Liu Y; Zhu T; Ma X; Liu R; Xu G; Meng L; Lu Y; Zhou J; Ma D
Clin Cancer Res; 2008 Sep; 14(17):5494-502. PubMed ID: 18765541
[TBL] [Abstract][Full Text] [Related]
30. A tumor-homing peptide with a targeting specificity related to lymphatic vessels.
Laakkonen P; Porkka K; Hoffman JA; Ruoslahti E
Nat Med; 2002 Jul; 8(7):751-5. PubMed ID: 12053175
[TBL] [Abstract][Full Text] [Related]
31. Structural evaluation of a novel pro-apoptotic peptide coupled to CNGRC tumor homing sequence by NMR.
Sandoval CM; Geierstanger BH; Fujimura S; Balatbat C; Williams T; de Unamuno J; Whiles-Lillig JA; Ellerby LM; Ellerby HM; Jennings P; Plesniak LA
Chem Biol Drug Des; 2006 Jun; 67(6):417-24. PubMed ID: 16882316
[TBL] [Abstract][Full Text] [Related]
32. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
Lee TY; Lin CT; Kuo SY; Chang DK; Wu HC
Cancer Res; 2007 Nov; 67(22):10958-65. PubMed ID: 18006841
[TBL] [Abstract][Full Text] [Related]
33. S4(13)-PV cell penetrating peptide and cationic liposomes act synergistically to mediate intracellular delivery of plasmid DNA.
Trabulo S; Mano M; Faneca H; Cardoso AL; Duarte S; Henriques A; Paiva A; Gomes P; Simões S; de Lima MC
J Gene Med; 2008 Nov; 10(11):1210-22. PubMed ID: 18729238
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of estradiol-chlorambucil hybrids as anticancer agents.
Gupta A; Saha P; Descôteaux C; Leblanc V; Asselin E; Bérubé G
Bioorg Med Chem Lett; 2010 Mar; 20(5):1614-8. PubMed ID: 20137939
[TBL] [Abstract][Full Text] [Related]
35. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules.
De Coupade C; Fittipaldi A; Chagnas V; Michel M; Carlier S; Tasciotti E; Darmon A; Ravel D; Kearsey J; Giacca M; Cailler F
Biochem J; 2005 Sep; 390(Pt 2):407-18. PubMed ID: 15859953
[TBL] [Abstract][Full Text] [Related]
36. Enhanced cell penetration of acid-degradable particles functionalized with cell-penetrating peptides.
Cohen JL; Almutairi A; Cohen JA; Bernstein M; Brody SL; Schuster DP; Fréchet JM
Bioconjug Chem; 2008 Apr; 19(4):876-81. PubMed ID: 18318462
[TBL] [Abstract][Full Text] [Related]
37. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach.
Varghese OP; Sun W; Hilborn J; Ossipov DA
J Am Chem Soc; 2009 Jul; 131(25):8781-3. PubMed ID: 19499915
[TBL] [Abstract][Full Text] [Related]
38. CyLoP-1: a novel cysteine-rich cell-penetrating peptide for cytosolic delivery of cargoes.
Jha D; Mishra R; Gottschalk S; Wiesmüller KH; Ugurbil K; Maier ME; Engelmann J
Bioconjug Chem; 2011 Mar; 22(3):319-28. PubMed ID: 21319732
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery.
Gilad Y; Noy E; Senderowitz H; Albeck A; Firer MA; Gellerman G
Bioorg Med Chem; 2016 Jan; 24(2):294-303. PubMed ID: 26719208
[TBL] [Abstract][Full Text] [Related]
40. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.
Hansel W; Enright F; Leuschner C
Mol Cell Endocrinol; 2007 Jan; 260-262():183-9. PubMed ID: 17101210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
